A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)

Inclusion criteria: Participants with a locally advanced or metastatic solid tumor that has progressed on or is intolerant to standard therapy, or for which no standard therapy exists. Prior multikinase inhibitors (MKIs) with anti-RET activity are allowed.

Sponsor/Collaborator: Loxo Oncology, Inc.|Eli Lilly and Company

Contact and Locations:
There may be multiple sites in this clinical trial
Phone Number: 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559
Email: ClinicalTrials.gov@lilly.com
Locations: https://classic.clinicaltrials.gov/ct2/show/NCT03157128

Mechanism of action: Selpercatinib, also known as LOXO-292, is a highly selective and potent, oral inhibitor for the treatment of patients with cancers that harbor abnormalities in the RET kinase.

Phases: Phase 1, Phase 2

NCT Number: NCT03157128

Status: Recruiting

Back to clinical trials list